Stock Performance and Market Context
On 01 Oct 2026, Sanofi Consumer Healthcare India Ltd recorded a day decline of 1.41%, closing near its lowest ever price point. This drop outpaced the Sensex’s marginal fall of 0.11% on the same day, underscoring the stock’s relative weakness. The share price has been on a three-day losing streak, cumulatively falling 5.4% during this period. Intraday volatility was notably high at 9.95%, indicating significant price fluctuations within the trading session.
The stock’s performance over longer durations further highlights its struggles. Over the past one year, it has delivered a negative return of 20.94%, nearly double the Sensex’s decline of 10.60%. The underperformance extends to shorter and medium-term periods as well, with losses of 8.93% over one month and 18.63% over three months, compared to the Sensex’s respective declines of 5.90% and 5.88%. Year-to-date, the stock has fallen 17.09%, slightly worse than the benchmark’s 15.04% drop.
Notably, the stock has failed to generate any positive returns over the past three and five years, standing at 0.00%, while the Sensex has appreciated by 9.98% and 23.20% respectively. Over a decade, the divergence is even more pronounced, with the benchmark rising 159.82% against no gains for Sanofi Consumer Healthcare.
Technical Indicators Signal Bearish Momentum
Technical analysis corroborates the bearish sentiment surrounding the stock. The overall trend is classified as bearish since 25 Sep 2026, when the price crossed below ₹3,953.15. The stock is trading below all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – reinforcing the downward momentum.
Key technical indicators such as MACD, Bollinger Bands, KST, and Dow Theory all signal bearish trends on weekly and monthly charts. The Relative Strength Index (RSI) shows a bullish signal on the weekly timeframe but remains inconclusive monthly. Immediate support is identified at ₹3,747.60, close to the current price and the 52-week low, while resistance levels lie at ₹4,034.63 (20-day moving average) and higher at ₹4,467.95 (100-day moving average).
Delivery volumes have shown a mixed pattern, with a 34.1% increase over the past month and a 47.47% rise in one-day delivery volume compared to the five-day average, suggesting active trading interest despite the downtrend.
Valuation and Financial Metrics
Sanofi Consumer Healthcare India Ltd is classified as a small-cap company within the Pharmaceuticals & Biotechnology sector. Its current market valuation reflects a Price to Earnings (P/E) ratio of 33x and a Price to Book Value (P/BV) of 22.83x, indicating a relatively expensive valuation despite the share price decline. The company’s Enterprise Value to EBITDA stands at 23.78x, and the PEG ratio is 2.00x, suggesting that earnings growth expectations are not fully aligned with the current price.
The stock’s dividend yield is 1.97%, with a recent dividend payout of ₹75 per share and a payout ratio of 71.85%. The ex-dividend date was 19 Jun 2026. Despite the high valuation multiples, the stock is trading at a discount relative to its peers’ historical averages, reflecting market caution.
Financial Performance and Growth Trends
Over the last five years, Sanofi Consumer Healthcare has exhibited modest growth, with net sales increasing at an annualised rate of 10.10% and operating profit growing at 5.70%. While these figures indicate steady expansion, they fall short of more robust sector benchmarks. The company’s return on equity (ROE) is notably high at 69.3%, reflecting efficient capital utilisation, though this is accompanied by a high Price to Book ratio, which may temper valuation appeal.
Recent quarterly results show positive trends, with net sales for the nine months ending June 2026 reaching ₹715.90 crores, a growth of 26.89%. The company reported its highest quarterly profit after tax (PAT) of ₹68.80 crores and earnings per share (EPS) of ₹29.91. These figures demonstrate operational profitability and management effectiveness despite the stock’s price pressures.
Quality and Capital Structure
Sanofi Consumer Healthcare India Ltd maintains a strong balance sheet, being net-debt free and exhibiting excellent capital structure metrics. The company’s interest coverage ratio is robust at 100x, and it has no promoter share pledging. Institutional investors hold a significant 20.46% stake, indicating confidence from entities with substantial analytical resources.
The company’s quality grade is classified as good, supported by excellent management risk assessment and capital structure, though growth metrics are below average. The average return on capital employed (ROCE) is weak at -178.66%, contrasting with the very strong ROE of 67.74%, suggesting some inefficiencies in capital deployment.
Comparative Performance and Market Position
Sanofi Consumer Healthcare’s stock has consistently underperformed the BSE500 index over the last three annual periods, reflecting challenges in maintaining competitive market positioning. The stock’s returns have lagged behind sector and benchmark indices across multiple time horizons, underscoring the persistent downward pressure on its valuation.
Despite the recent positive quarterly results and strong management efficiency, the stock’s price performance remains subdued, with the current level near the all-time low of ₹3,755.1. This price point is just 0.14% above the 52-week low of ₹3,747.60, highlighting the severity of the decline.
Summary of Key Metrics as of 01 Oct 2026
• Current Price: ₹3,752.80
• 52-Week High: ₹5,241.35
• 52-Week Low: ₹3,747.60
• Market Cap Grade: Small-cap
• Mojo Score: 43.0 (Sell Grade, downgraded from Hold on 10 Aug 2026)
• Day Change: -1.41%
• 1-Year Return: -20.94%
• P/E Ratio: 33x
• P/BV: 22.83x
• PEG Ratio: 2.00x
• Dividend Yield: 1.97%
• Institutional Holdings: 20.46%
Sanofi Consumer Healthcare India Ltd’s stock remains under pressure, trading below all major moving averages and near historic lows. The company’s financials show a mixed picture of steady sales growth and strong profitability metrics, yet the market valuation and price performance reflect ongoing challenges in sustaining investor confidence.
